Tissue Penetration Of Meropenem In Patients Undergoing Gynecologic Surgery

The purpose of this study was to assess the tissue-penetrating ability of a new beta-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at similar to 1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at similar to 1 hour was 13.3 mu g/mL. The median fluid and tissue concentrations at similar to 1 hour were as follows: cervix, 8.5 mu g/g; endometrium, 2.3 mu g/g; fallopian tube, 1.9 mu g/g; myometrium, 3.6 mu g/g; ovary, 2.3 mu g/g; and uterus, 2.3 mu g/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.